DrugPatentWatch Database Preview

Osimertinib mesylate - Generic Drug Details

  Purchase this report

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for osimertinib mesylate and what is the scope of osimertinib mesylate freedom to operate?

Osimertinib mesylate is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Osimertinib mesylate has eighty-one patent family members in thirty-eight countries.

There is one drug master file entry for osimertinib mesylate. One supplier is listed for this compound.

Summary for osimertinib mesylate

International Patents:	81
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	25
Clinical Trials:	542
Patent Applications:	3
DailyMed Link:	osimertinib mesylate at DailyMed

Pharmacology for osimertinib mesylate

Drug Class	Kinase Inhibitor
Mechanism of Action	Kinase Inhibitors Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inducers Cytochrome P450 1A2 Inducers Breast Cancer Resistance Protein Inhibitors

Synonyms for osimertinib mesylate

1421373-66-1

2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, methanesulfonate (1:1)

AK198680

AKOS026673944

AZD 9291 mesylate

AZD-9291 (Mesylate)

AZD-9291 mesylate

AZD-9291 mesylate pound Osimertinib Mereletinib)

AZD9291 mesylate

AZD9291 Ms salt, Osimertinib Ms salt; Mereletinib Ms salt

BC600811

CHEBI:90948

CHEMBL3545063

D10766

EX-A1577

FT-0699962

HY-15772A

KS-00000SU8

Mereletinib mesylate

MFCD28137994

MolPort-044-560-736

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate

N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide methanesulfonate

Osimertinib mesilate (JAN)

Osimertinib mesylate (USAN)

Osimertinib mesylate [USAN]

osimertinib methanesulfonate

osimertinib monomesylate

RDL94R2A16

SCHEMBL14661152

Tagrisso (TN)

UNII-RDL94R2A16

US Patents and Regulatory Information for osimertinib mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-001	Nov 13, 2015		RX	Yes	No
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-001	Nov 13, 2015		RX	Yes	No
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-001	Nov 13, 2015		RX	Yes	No			Y	Y
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-001	Nov 13, 2015		RX	Yes	No

  Purchase this report

or, see our see our flat-rate plans

  Purchase this report

or, see our see our flat-rate plans

International Patents for osimertinib mesylate

Country	Document Number	Estimated Expiration
Canada	2881993
New Zealand	617393
China	105348266
Taiwan	201443040